- Advanced Proteome Therapeutics Corporation’s (APC) subsidiary receives notice of allowance for patent claims covering key intellectual property
- The technology enables the development of highly effective antibody-drug therapies
- The claims cover antibody conjugate compositions produced with a two step technology
- It broadly cover antibodies as a class and different classes of payloads including toxins, drugs, and chelators
- Advanced Proteome Therapeutics Corporation (APC) is up 28.57 per cent and is trading at $0.18 per share as of 11:59 a.m. ET
Advanced Proteome Therapeutics (APC) subsidiary Advanced Proteome Therapeutics has received a notice of allowance for patent claims covering key intellectual property.
Through the subsidiary, a proprietary protein conjugation technology has been invented. The technology enables the development of highly effective antibody-drug therapies through improved site-specific labelling, drug-antibody ratio control, and combination payloads.
The first set of claims from a U.S. patent application has been approved. The claims cover the antibody conjugate compositions produced with APTI’s two-step conjugation technology. It also includes products for the first step, which determines an essential amino acid site-selectiveness, and the second step where a linker and payload are attached creating complete antibody-drug conjugates (ADCs).
The claims broadly cover antibodies as a class and different classes of payloads including toxins, drugs and chelators.
APTI plans to continue pursuing expanded claims and additional patent families within the initial application to create additional layers of intellectual property protection. The notice of allowance will be followed by patent issuance pending fee payments and processing.
Paul Woodward, President of Advanced Proteome, commented,
“The allowance of our claims was a somewhat lengthy process; however, we are gratified that our allowed claims reflect the superior results obtained by our technology.”
The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to the current state-of-the-art linker technology.
The company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development.
Advanced Proteome Therapeutics Corporation (APC) is up 28.57 per cent and is trading at $0.18 per share as of 11:59 a.m. ET.
